Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 221 participants.

Also called NCT01115855

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 221 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01115855
Other papers using this trial's data
  • Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF) Circulation journal : official journal of the Japanese Circulation Society, 2017-12-25 DOI, PubMed 28824029

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01115855. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-10-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
Acronym
J-EMPHASIS-HF
Condition
Heart Failure
Intervention (Drug)
Eplerenone
Intervention (Drug)
Placebo
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (class: industry)

Record details

Record id
cardio:ct-nct01115855
Content hash
44e714b50e407718c63d03c5e6345cc50b42b521e858b8afad4cfbd28a1df6e8